Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS
Phase of Trial: Phase II/III
Latest Information Update: 27 May 2016
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Pharmacodynamics; Proof of concept; Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 12 May 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 11 Jan 2016 Change in study design as randomized and double blind, primary end points and patient age limit as reported by ClinicalTrials.gov record.
- 11 Jan 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.